Histidine-Rich Glycoprotein Alleviates Liver Ischemia/Reperfusion Injury in Mice With Nonalcoholic Steatohepatitis.
Journal
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
28
09
2020
received:
27
03
2020
accepted:
03
11
2020
pubmed:
2
12
2020
medline:
17
6
2021
entrez:
1
12
2020
Statut:
ppublish
Résumé
Hepatic ischemia/reperfusion injury (IRI) is a major complication of liver surgery and transplantation, especially in patients with nonalcoholic steatohepatitis (NASH). The mechanism of NASH susceptibility to IRI has not been fully clarified. We investigated the role of liver-produced histidine-rich glycoprotein (HRG) in NASH IRI. A NASH mouse model was established using C57BL/6J mice fed a methionine-choline-deficient diet (MCDD) for 6 weeks. The MCDD and standard diet groups were exposed to 60 minutes of partial hepatic ischemia/reperfusion (I/R). We further evaluated the impact of HRG in this context using HRG knockdown (KD) mice. IRI increased HRG expression in the standard diet group, but not in the MCDD group after I/R. HRG expression was inversely correlated with neutrophil infiltration and the formation of neutrophil extracellular traps (NETs). HRG KD mice showed severe liver injury with neutrophil infiltration and the formation of NETs. Pretreatment with supplementary HRG protected against I/R with the inhibition of neutrophil infiltration and the formation of NETs. In vitro, hepatocytes showed that the expression of HRG was upregulated under hypoxia/reoxygenation conditions, but not in response to oleic acid-treated hepatocytes. The decrease in HRG expression in fatty hepatocytes was accompanied by decreased farnesoid X receptor and hypoxia inducible factor 2 alpha subunit expression. HRG is a hepatoprotective factor during hepatic IRI because it decreases neutrophil infiltration and the formation of NETs. The decrease in HRG is a cause of susceptibility to IRI in steatotic livers. Therefore, HRG is a new therapeutic target for minimizing liver damage in patients with NASH.
Identifiants
pubmed: 33259137
doi: 10.1002/lt.25960
pii: 01445473-202106000-00011
doi:
Substances chimiques
Proteins
0
histidine-rich proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
840-853Subventions
Organisme : JSPS KAKENHI
ID : JP15K10169
Informations de copyright
Copyright © 2021 by the American Association for the Study of Liver Diseases.
Références
Eltzschig HK, Eckle T. Ischemia and reperfusion—from mechanism to translation. Nat Med 2011;17:1391‐1401.
Zhai Y, Busuttil RW, Kupiec‐Weglinski JW. Liver ischemia and reperfusion injury: new insights into mechanisms of innate‐adaptive immune‐mediated tissue inflammation. Am J Transplant 2011;11:1563‐1569.
Gehrau RC, Mas VR, Dumur CI, Suh JL, Sharma AK, Cathro HP, et al. Donor hepatic steatosis induce exacerbated ischemia‐reperfusion injury through activation of innate immune response molecular pathways. Transplantation 2015;99:2523‐2533.
Dar WA, Sullivan E, Bynon JS, Eltzschig H, Ju C. Ischemia reperfusion injury in liver transplantation: cellular and molecular mechanisms. Liver Int 2019;39:788‐801.
Alvarez‐Mercado AI, Gulfo J, Gomez MR, Jimenez‐Castro MB, Gracia‐Sancho J, Peralta C. Use of steatotic grafts in liver transplantation: current status. Liver Transpl 2019;25:771‐786.
Koide T, Foster D, Yoshitake S, Davie EW. Amino acid sequence of human histidine‐rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochemistry 1986;25:2220‐2225.
Leung LL. Interaction of histidine‐rich glycoprotein with fibrinogen and fibrin. J Clin Invest 1986;77:1305‐1311.
Silverstein RL, Leung LL, Harpel PC, Nachman RL. Platelet thrombospondin forms a trimolecular complex with plasminogen and histidine‐rich glycoprotein. J Clin Invest 1985;75:2065‐2073.
Gorgani NN, Parish CR, Easterbrook Smith SB, Altin JG. Histidine‐rich glycoprotein binds to human IgG and C1q and inhibits the formation of insoluble immune complexes. Biochemistry 1997;36:6653‐6662.
Morgan WT. The histidine‐rich glycoprotein of serum has a domain rich in histidine, proline, and glycine that binds heme and metals. Biochemistry 1985;24:1496‐1501.
Poon IK, Hulett MD, Parish CR. Histidine‐rich glycoprotein is a novel plasma pattern recognition molecule that recruits IgG to facilitate necrotic cell clearance via FcgammaRI on phagocytes. Blood 2010;115:2473‐2482.
Donate F, Juarez JC, Guan X, Shipulina NV, Plunkett ML, Tel‐Tsur Z, et al. Peptides derived from the histidine‐proline domain of the histidine‐proline‐rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities. Cancer Res 2004;64:5812‐5817.
Juarez JC, Guan X, Shipulina NV, Plunkett ML, Parry GC, Shaw DE, et al. Histidine‐proline‐rich glycoprotein has potent antiangiogenic activity mediated through the histidine‐proline‐rich domain. Cancer Res 2002;62:5344‐5350.
Wake H, Mori S, Liu K, Takahashi HK, Nishibori M. Histidine‐rich glycoprotein inhibited high mobility group box 1 in complex with heparin‐induced angiogenesis in matrigel plug assay. Eur J Pharmacol 2009;623:89‐95.
Wake H, Mori S, Liu K, Morioka Y, Teshigawara K, Sakaguchi M, et al. Histidine‐rich glycoprotein prevents septic lethality through regulation of immunothrombosis and inflammation. EBioMedicine 2016;9:180‐194.
Selzner N, Selzner M, Jochum W, Amann‐Vesti B, Graf R, Clavien PA. Mouse livers with macrosteatosis are more susceptible to normothermic ischemic injury than those with microsteatosis. J Hepatol. 2006;44:694‐701.
Lentsch AB, Yoshidome H, Cheadle WG, Miller FN, Edwards MJ. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein‐2 and Kupffer cells. Hepatology 1998;27:507‐512.
Tak E, Park GC, Kim SH, Jun DY, Lee J, Hwang S, et al. Epigallocatechin‐3‐gallate protects against hepatic ischaemia‐reperfusion injury by reducing oxidative stress and apoptotic cell death. J Int Med Res 2016;44:1248‐1262.
Huang H, Tohme S, Al‐Khafaji AB, Tai S, Loughran P, Chen L, et al. Damage‐associated molecular pattern‐activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury. Hepatology 2015;62:600‐614.
Patel KK, Poon IK, Talbo GH, Perugini MA, Taylor NL, Ralph TJ, et al. New method for purifying histidine‐rich glycoprotein from human plasma redefines its functional properties. IUBMB Life 2013;65:550‐563.
Moravcova A, Cervinkova Z, Kucera O, Mezera V, Rychtrmoc D, Lotkova H. The effect of oleic and palmitic acid on induction of steatosis and cytotoxicity on rat hepatocytes in primary culture. Physiol Res 2015;64(suppl 5):S627‐S636.
Andrade DR Jr, Andrade DR, Santos SA. Study of rat hepatocytes in primary culture submitted to hypoxia and reoxygenation: action of the cytoprotectors prostaglandin E1, superoxide dismutase, allopurinol and verapamil. Arq Gastroenterol 2009;46:333‐340.
Zang S, Wang L, Ma X, Zhu G, Zhuang Z, Xun Y, et al. Neutrophils play a crucial role in the early stage of nonalcoholic steatohepatitis via neutrophil elastase in mice. Cell Biochem Biophys 2015;73:479‐487.
Nakata R, Hyodo F, Murata M, Eto H, Nakaji T, Kawano T, et al. In vivo redox metabolic imaging of mitochondria assesses disease progression in non‐alcoholic steatohepatitis. Sci Rep 2017;7:17170.
Machado MV, Michelotti GA, Xie G, Almeida Pereira T, Boursier J, Bohnic B, et al. Mouse models of diet‐induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS One 2015;10:e0127991.
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313‐1321.
Yang YY, Huang YT, Lee TY, Chan CC, Yeh YC, Lee KC, et al. Rho‐kinase‐dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis. Liver Transpl 2012;18:1371‐1383.
Tevar AD, Clarke CN, Schuster R, Wang J, Edwards MJ, Lentsch AB. The effect of hepatic ischemia reperfusion injury in a murine model of nonalcoholic steatohepatitis. J Surg Res 2011;169:e7‐e14.
Morello E, Sutti S, Foglia B, Novo E, Cannito S, Bocca C, et al. Hypoxia‐inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine‐rich glycoprotein. Hepatology 2018;67:2196‐2214.
Liu LP, Hu BG, Ye C, Ho RL, Chen GG, Lai PB. HBx mutants differentially affect the activation of hypoxia‐inducible factor‐1alpha in hepatocellular carcinoma. Br J Cancer 2014;110:1066‐1073.
Lu L, Zhou H, Ni M, Wang X, Busuttil R, Kupiec‐Weglinski J, et al. Innate immune regulations and liver ischemia‐reperfusion injury. Transplantation 2016;100:2601‐2610.
Shibuya H, Ohkohchi N, Tsukamoto S, Satomi S. Tumor necrosis factor‐induced, superoxide‐mediated neutrophil accumulation in cold ischemic/reperfused rat liver. Hepatology 1997;26:113‐120.
He S, Atkinson C, Evans Z, Ellett JD, Southwood M, Elvington A, et al. A role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury. J Immunol 2009;183:4764‐4772.
Kojima I, Tanaka T, Inagi R, Kato H, Yamashita T, Sakiyama A, et al. Protective role of hypoxia‐inducible factor‐2alpha against ischemic damage and oxidative stress in the kidney. J Am Soc Nephrol 2007;18:1218‐1226.
Deuschle U, Birkel M, Hambruch E, Hornberger M, Kinzel O, Perovic‐Ottstadt S, et al. The nuclear bile acid receptor FXR controls the liver derived tumor suppressor histidine‐rich glycoprotein. Int J Cancer 2015;136:2693‐2704.
Ralph GS, Parham S, Lee SR, Beard GL, Craigon MH, Ward N, et al. Identification of potential stroke targets by lentiviral vector mediated overexpression of HIF‐1 alpha and HIF‐2 alpha in a primary neuronal model of hypoxia. J Cereb Blood Flow Metab 2004;24:245‐258.
Bangoura G, Yang LY, Huang GW, Wang W. Expression of HIF‐2alpha/EPAS1 in hepatocellular carcinoma. World J Gastroenterol 2004;10:525‐530.
Hu JL, Liu LP, Yang SL, Fang X, Wen L, Ren QG, et al. Hepatitis B virus induces hypoxia‐inducible factor‐2alpha expression through hepatitis B virus X protein. Oncol Rep 2016;35:1443‐1448.
Jungermann K, Kietzmann T. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology 2000;31:255‐260.
Qu A, Taylor M, Xue X, Matsubara T, Metzger D, Chambon P, et al. Hypoxia‐inducible transcription factor 2alpha promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology 2011;54:472‐483.
Campbell EL, Bruyninckx WJ, Kelly CJ, Glover LE, McNamee EN, Bowers BE, et al. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation. Immunity 2014;40:66‐77.
Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, et al. Mitochondrial complex III is required for hypoxia‐induced ROS production and cellular oxygen sensing. Cell Metab 2005;1:401‐408.
Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008;48:1632‐1643.